Concerning Chapter 5 – Human Albumin; in Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives, 4th ed. Transfus Med Hemother 2009;36(6):399–407

Publisher： Karger

E-ISSN： 1660-3818|37|2|98-99

ISSN： 1660-3796

Source： Transfusion Medicine and Hemotherapy, Vol.37, Iss.2, 2010-03, pp. : 98-99

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives (4th revised edition, 2008) – Suspension of Chapter 5 ’Human Albumin‘

By  

Transfusion Medicine and Hemotherapy, Vol. 36, Iss. 6, 2009-12 ,pp. : 399-407

Karger

Access to resources Recommend Favorite

Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives (4th revised edition, 2008) – Suspension of Chapter 5 ‘Human Albumin’

By  

Transfusion Medicine and Hemotherapy, Vol. 38, Iss. 1, 2011-01 ,pp. : 71-71

Karger

Access to resources Recommend Favorite

Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives: Chapter 5 Human Albumin - Revised

By  

Transfusion Medicine and Hemotherapy, Vol. 43, Iss. 3, 2016-05 ,pp. : 223-232

Karger

Access to resources Recommend Favorite

Concerning ‘Hepatitis C Virus’ (Transfus Med Hemother2003;30:239–250)

By  

Transfusion Medicine and Hemotherapy, Vol. 30, Iss. 6, 2003-12 ,pp. : 288-

Karger

Access to resources Recommend Favorite

Concerning Caspari et al: Pathogen Inactivation of Cellular Blood Products – More Security for the Patient or Less? Transfus Med Hemother 2003;30:261–263

By  

Transfusion Medicine and Hemotherapy, Vol. 32, Iss. 1, 2005-01 ,pp. : 45-48

Karger

Access to resources Recommend Favorite